ClinicalTrials.gg

Program

cabozantinib

Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.

Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.

Furthest: phase 4, since Jul 8, 201333 company-led studies, 8 open or runningNext primary completion: Aug 25, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixis237 open or runningphase 4since Jul 8, 2013Sep 20, 2005May 31, 2030phase 3 · NCT07620574
Bristol-Myers Squibb51 open or runningphase 3since May 3, 2017Nov 24, 2009Aug 25, 2029phase 2 · NCT03899155
Ipsen20 open or runningphase 2since May 9, 2019May 9, 2019none ahead
Takeda20 open or runningphase 2since Nov 8, 2017Nov 8, 2017none ahead
Academic Thoracic Oncology Medical Investigators Consortium10 open or runningphase 2since Apr 23, 2018Apr 23, 2018none ahead

Also a collaborator on its studies: Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, roche-genentech and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Sep 20, 2005.

  1. May 3, 2017Phase 3 study in Carcinoma, Renal CellBristol-Myers Squibb · NCT03141177 · 701 enrolled · United States, Argentina, Australia and more
  2. May 23, 2017Phase 1 study in Carcinoma, Transitional CellExelixis · NCT03170960 · 914 enrolled · United States, Australia, Belgium and more
  3. Nov 8, 2017Takeda's first study: phase 2 study in Advanced Renal Cell CarcinomaNew to TakedaTakeda · NCT03339219 · 35 enrolled · Japan
  4. Apr 23, 2018Academic Thoracic Oncology Medical Investigators Consortium's first study: phase 2 study in Colorectal NeoplasmsNew to Academic Thoracic Oncology Medical Investigators ConsortiumAcademic Thoracic Oncology Medical Investigators Consortium · NCT03542877 · 44 enrolled · United States
  5. Jun 29, 2018Phase 2 study in Advanced Hepatocellular CarcinomaTakeda · NCT03586973 · 34 enrolled · Japan
  6. Sep 26, 2018Phase 3 study in Thyroid Cancer, PapillaryExelixis · NCT03690388 · 187 enrolled · United States, Argentina, Australia and more
  7. Nov 26, 2018Phase 3 study in Carcinoma, HepatocellularExelixis · NCT03755791 · 837 enrolled · United States, Argentina, Australia and more
  8. Apr 1, 2019Phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155 · 1,500 planned · United States, Argentina, Australia and more
  9. May 2, 2019Phase 3 study in Carcinoma, Renal CellExelixis · NCT03937219 · 855 enrolled · United States, Argentina, Australia and more
  10. May 9, 2019Ipsen's first study: phase 2 study in Carcinoma, Renal CellNew to IpsenIpsen · NCT03945773 · 127 enrolled · Austria, France, Germany and more
  11. Nov 1, 2019Phase 2 study in CarcinomaBristol-Myers Squibb · NCT04151563 · United States, Argentina, Belgium and more
  12. Jun 22, 2020Phase 3 study in Prostatic NeoplasmsExelixis · NCT04446117 · 575 enrolled · United States, Argentina, Australia and more
  13. Mar 4, 2024Phase 2 study in OsteosarcomaIpsen · NCT06341712 · 10 enrolled · United States, Belgium, Canada and more
  14. May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States

Ahead

  1. Aug 25, 2029Primary completion: phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155
  2. May 31, 2030Primary completion: phase 3 study in NeoplasmsExelixis · NCT07620574

TargetBeta

KDR →MET →read by rule
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
zanzalintinibruleExelixisphase 317

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07620574Neoplasms · United States3By invitationExelixisMay 31, 20305,000
NCT06341712Osteosarcoma · United States, Belgium, Canada and more2TerminatedIpsenFeb 27, 202610
NCT04446117Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingExelixisApr 19, 2024575
NCT04151563Carcinoma · United States, Argentina, Belgium and more2WithdrawnBristol-Myers SquibbDec 17, 20230
NCT03945773Carcinoma, Renal Cell · Austria, France, Germany and more2CompletedIpsenMay 11, 2023127
NCT03937219Carcinoma, Renal Cell · United States, Argentina, Australia and more3Active, not recruitingExelixisJan 31, 2022855
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingBristol-Myers SquibbAug 25, 20291,500
NCT03755791Carcinoma, Hepatocellular · United States, Argentina, Australia and more3Active, not recruitingExelixisNov 30, 2021837
NCT03690388Thyroid Cancer, Papillary · United States, Argentina, Australia and more3Active, not recruitingExelixisAug 19, 2020187
NCT03586973Advanced Hepatocellular Carcinoma · Japan2CompletedTakedaJul 17, 201934
NCT03542877Colorectal Neoplasms · United States2CompletedAcademic Thoracic Oncology Medical Investigators ConsortiumOct 19, 202044
NCT03339219Advanced Renal Cell Carcinoma · Japan2CompletedTakedaAug 25, 202035
NCT03170960Carcinoma, Transitional Cell · United States, Australia, Belgium and more1Active, not recruitingExelixisFeb 21, 2023914
NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedBristol-Myers SquibbFeb 12, 2020701
NCT01995058Prostatic Neoplasms · United States2TerminatedExelixisNov 201454
NCT01908426Carcinoma, Hepatocellular · United States, Australia, Belgium and more3CompletedExelixisOct 16, 2017707
NCT01896479Carcinoma, Medullary · Australia, Canada, Croatia and more4Active, not recruitingExelixisJul 15, 2020247
NCT01865747Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedExelixisMay 22, 2015658
NCT01761773Renal Insufficiency · United States1CompletedExelixisApr 201332
NCT01658878Carcinoma, Hepatocellular · United States, Canada, France and more2CompletedBristol-Myers SquibbNov 12, 2024657
NCT01605227Prostatic Neoplasms · United States, Australia, Austria and more3CompletedExelixisSep 20141,028
NCT01553656Neoplasms · Japan1CompletedExelixisMay 201585
NCT01522443Prostatic Neoplasms · United States, Australia, Canada and more3TerminatedExelixisOct 2014119
NCT01493869Healthy · United States1CompletedExelixisMay 201426
NCT01100619Thyroid Cancer, Papillary · United States1CompletedExelixisAug 201240
NCT01068782Glioblastoma · United States, Canada2TerminatedExelixisMay 201119
NCT01018745Neoplasms · Japan1CompletedBristol-Myers SquibbJul 20103
NCT00960492Glioblastoma · United States1CompletedExelixisNov 201226
NCT00940225Neoplasms · United States, Belgium, Israel and more2CompletedExelixisMay 2013730
NCT00704730Thyroid Neoplasms · United States, Austria, Belgium and more3CompletedExelixisOct 2011330
NCT00704288Glioblastoma · United States2CompletedExelixisJun 2012222
NCT00596648Carcinoma, Non-Small-Cell Lung · United States2CompletedExelixisAug 2, 201292
NCT00215605Lymphoma · United States1CompletedExelixisApr 201185

How it is read

Names in the registry

  • “Cabozantinib”, 18 entries
  • “cabozantinib”, 9 entries
  • “XL184”, 6 entries
  • “Cabozantinib tablets”, 2 entries
  • “Cabozantinib (XL184) 140 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.